Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE A SALZBERG

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1376528943
CMS profile
243136
Location
SUWANEE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$87,088.72

183 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE A SALZBERG

NPI 1376528943 · CMS profile ID 243136

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SUWANEE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

183 matching records · $87,088.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 183 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 183.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7912/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684920703 CMS
AbbVie, Inc. $23.9012/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648063571 CMS
Ferring Pharmaceuticals Inc. $12.1812/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655215529 CMS
Gilead Sciences, Inc. $25.0212/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681597147 CMS
Janssen Biotech, Inc. $20.2512/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688771 CMS
Celgene Corporation $43.9512/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672982279 CMS
Janssen Biotech, Inc. $4.6412/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688767 CMS
PFIZER INC. $14.1412/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673698749 CMS
PFIZER INC. $20.6312/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673777189 CMS
PFIZER INC. $148.0311/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673832237 CMS
PFIZER INC. $131.7911/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673833255 CMS
PFIZER INC. $426.3611/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673836429 CMS
Allergan Inc. $2.9111/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671078479 CMS
Janssen Scientific Affairs, LLC $2,575.0011/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606117 CMS
Janssen Scientific Affairs, LLC $4,025.0011/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606119 CMS
Janssen Biotech, Inc. $21.9511/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688763 CMS
PFIZER INC. $3.0311/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673775859 CMS
Janssen Biotech, Inc. $18.0011/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688760 CMS
Janssen Scientific Affairs, LLC $2,282.9011/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606113 CMS
Janssen Scientific Affairs, LLC $112.6211/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606115 CMS
PFIZER INC. $14.1711/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673836563 CMS
Janssen Scientific Affairs, LLC $77.4011/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606111 CMS
PFIZER INC. $253.5511/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673829913 CMS
PFIZER INC. $303.1011/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673830175 CMS
Janssen Biotech, Inc. $1.5811/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688756 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $3.3411/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684920699 CMS
AbbVie, Inc. $12.8611/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648063567 CMS
Takeda Pharmaceuticals U.S.A., Inc. $84.1011/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681872095 CMS
Janssen Biotech, Inc. $18.5411/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688753 CMS
Janssen Scientific Affairs, LLC $1,150.0011/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606099 CMS
Janssen Scientific Affairs, LLC $2,575.0011/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606101 CMS
Janssen Scientific Affairs, LLC $4,025.0011/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606103 CMS
Janssen Scientific Affairs, LLC $521.2511/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606105 CMS
Janssen Scientific Affairs, LLC $1,196.5011/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606107 CMS
Janssen Scientific Affairs, LLC $119.8111/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606109 CMS
AbbVie, Inc. $4.8711/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648063569 CMS
Janssen Biotech, Inc. $4.1010/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688749 CMS
Janssen Scientific Affairs, LLC $124.5810/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606097 CMS
AbbVie, Inc. $22.2710/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648063565 CMS
Janssen Biotech, Inc. $15.1910/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658688737 CMS
PFIZER INC. $7.9710/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673169027 CMS
PFIZER INC. $14.0110/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673171361 CMS
Janssen Pharmaceuticals, Inc $38.0010/17/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659259319 CMS
Janssen Pharmaceuticals, Inc $38.0010/17/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659259321 CMS
AbbVie, Inc. $5.1610/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648063561 CMS
Janssen Scientific Affairs, LLC $4,025.0010/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606095 CMS
Janssen Scientific Affairs, LLC $42.9710/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606093 CMS
Janssen Scientific Affairs, LLC $28.8610/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606089 CMS
Janssen Scientific Affairs, LLC $30.6210/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606091 CMS
Janssen Scientific Affairs, LLC $859.3710/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657606085 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $87,088.72 183
PY2020 $25,152.08 58
PY2021 $17,526.51 124
PY2022 $46,620.72 107
PY2023 $41,911.39 77
PY2024 $16,306.24 46
PY2025 $40,647.25 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $35,777.10 3
PY2023 Principal investigator $4,640.61 4
PY2022 Principal investigator $52,325.70 12
PY2021 Principal investigator $131,307.67 47
PY2020 Recipient $7,898.24 3
PY2020 Principal investigator $335,230.92 133
PY2019 Recipient $12,040.75 4
PY2019 Principal investigator $611,218.71 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

136 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $951.68 12/31/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 721318565
Principal investigator 1 Allergan, Inc. $1,905.00 12/31/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh No dispute reported 06/30/2026 721318659
Principal investigator 1 AbbVie Inc. $1,312.28 12/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721203825
Principal investigator 1 AbbVie Inc. $10,292.40 12/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721203847
Principal investigator 1 Gilead Sciences, Inc. $1,353.00 12/23/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 742088889
Principal investigator 1 Janssen Research & Development, LLC $1,339.26 12/12/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487673
Principal investigator 1 Janssen Research & Development, LLC $1,921.55 12/12/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487679
Principal investigator 1 AbbVie Inc. $2,282.40 12/07/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721200011
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,242.90 12/01/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 737093447
Principal investigator 1 Janssen Research & Development, LLC $16.86 11/30/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487667
Principal investigator 1 Janssen Research & Development, LLC $21.60 11/30/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487669
Principal investigator 1 Janssen Research & Development, LLC $3,426.00 11/19/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis No dispute reported 06/30/2026 719487599
Principal investigator 1 Gilead Sciences, Inc. $1,363.00 11/18/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088887
Principal investigator 1 AbbVie Inc. $1,079.18 10/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721193861
Principal investigator 1 AbbVie Inc. $3,075.60 10/29/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721193577
Principal investigator 1 Genentech, Inc. $3,904.60 10/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
INDXN MAIN ETRO PBO No dispute reported 06/30/2026 857142267
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) No dispute reported 06/30/2026 737091175
Principal investigator 1 Janssen Research & Development, LLC $10,970.00 10/26/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719485255
Principal investigator 1 Janssen Research & Development, LLC $8,772.00 10/26/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485259
Principal investigator 1 PFIZER INC. $35.94 10/22/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 742929853
Principal investigator 1 PFIZER INC. $682.81 10/22/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 742929857
Principal investigator 1 AbbVie Inc. $579.10 10/21/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
P11-282 No dispute reported 06/30/2026 721191637
Principal investigator 1 Gilead Sciences, Inc. $135.00 10/21/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088885
Principal investigator 1 Janssen Research & Development, LLC $250.00 10/15/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719485251
Principal investigator 1 AbbVie Inc. $3,220.80 09/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-675 No dispute reported 06/30/2026 721188551
Principal investigator 1 AbbVie Inc. $57.60 09/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721189281
Principal investigator 1 AbbVie Inc. $1,290.86 09/28/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721187163
Principal investigator 1 AbbVie Inc. $502.50 09/28/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-430 No dispute reported 06/30/2026 721187255
Principal investigator 1 Janssen Research & Development, LLC $200.00 09/25/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485247
Principal investigator 1 Gilead Sciences, Inc. $1,671.00 09/23/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 742088881
Principal investigator 1 Gilead Sciences, Inc. $2,192.00 09/23/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 09/22/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
EFFICACY AND SAFETY OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN?S DISEASE (CARMEN CD 307) No dispute reported 06/30/2026 737088773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 09/22/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
EFFICACY AND SAFETY OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN?S DISEASE (CARMEN CD 307) No dispute reported 06/30/2026 737088775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,055.00 09/22/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 737088809
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,288.16 09/21/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, Pc
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 736758907
Principal investigator 1 AbbVie Inc. $1,484.40 09/09/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721185537
Principal investigator 1 Allergan, Inc. $700.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721295111
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,131.30 09/01/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 302) No dispute reported 06/30/2026 737087385
Principal investigator 1 AbbVie Inc. $37.80 08/31/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721184251
Principal investigator 1 Janssen Research & Development, LLC $1,462.00 08/24/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485243
Principal investigator 1 Janssen Research & Development, LLC $1,162.00 08/24/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis No dispute reported 06/30/2026 719487591
Principal investigator 1 Gilead Sciences, Inc. $3,885.00 08/19/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088879
Principal investigator 1 AbbVie Inc. $1,029.60 08/04/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721179459
Principal investigator 1 Janssen Research & Development, LLC $4,944.00 07/27/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 719487659
Principal investigator 1 Janssen Research & Development, LLC $6,937.00 07/27/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 719487663
Principal investigator 1 AbbVie Inc. $569.79 07/23/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
P11-282 No dispute reported 06/30/2026 721176595
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286489
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286545
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721286609
Principal investigator 1 Allergan, Inc. $86.00 07/23/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721287143
Principal investigator 1 Allergan, Inc. $86.00 07/21/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721285743
Principal investigator 1 Allergan, Inc. $86.00 07/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721283505
Principal investigator 1 AbbVie Inc. $1,196.36 07/06/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721174923
Principal investigator 1 AbbVie Inc. $195.00 07/01/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-430 No dispute reported 06/30/2026 721174241
Principal investigator 1 AbbVie Inc. $100.00 06/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-431 No dispute reported 06/30/2026 721173803
Recipient UCB Biosciences Inc. $7,800.00 06/22/2020 Covered Recipient Physician A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol CIMZIA For Crohn's Disease No dispute reported 06/30/2026 746122611
Principal investigator 1 Janssen Research & Development, LLC $1,232.00 06/19/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719485239
Principal investigator 1 Gilead Sciences, Inc. $1,353.00 06/17/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 742088877
Principal investigator 1 Janssen Research & Development, LLC $2,324.00 06/10/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis No dispute reported 06/30/2026 719487595
Principal investigator 1 Janssen Research & Development, LLC $762.60 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487611
Principal investigator 1 Janssen Research & Development, LLC $252.70 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487615
Principal investigator 1 Janssen Research & Development, LLC $540.06 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487619
Principal investigator 1 Janssen Research & Development, LLC $7.86 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487623
Principal investigator 1 Janssen Research & Development, LLC $36.26 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487627
Principal investigator 1 Janssen Research & Development, LLC $29.03 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487631
Principal investigator 1 Janssen Research & Development, LLC $34.74 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487635
Principal investigator 1 Janssen Research & Development, LLC $45.88 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487639
Principal investigator 1 Janssen Research & Development, LLC $17.34 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487643
Principal investigator 1 Janssen Research & Development, LLC $49.48 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487647
Principal investigator 1 Janssen Research & Development, LLC $141.00 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487649
Principal investigator 1 Janssen Research & Development, LLC $373.60 06/09/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719487653
Principal investigator 1 PFIZER INC. $1,717.14 06/04/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 742941531
Principal investigator 1 AbbVie Inc. $2,302.80 05/29/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721168761
Principal investigator 1 AbbVie Inc. $2,706.00 05/28/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-431 No dispute reported 06/30/2026 721168531
Principal investigator 1 AbbVie Inc. $146.25 05/28/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-433 No dispute reported 06/30/2026 721168543
Principal investigator 1 AbbVie Inc. $1,469.78 05/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721167419
Principal investigator 1 Janssen Research & Development, LLC $1,531.00 05/25/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485236
Principal investigator 1 Gilead Sciences, Inc. $2,726.00 05/20/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088875
Principal investigator 1 Genentech, Inc. $2,425.50 05/14/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 857142261
Principal investigator 1 AbbVie Inc. $5,498.00 04/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-675 No dispute reported 06/30/2026 721163699
Principal investigator 1 AbbVie Inc. $2,891.20 04/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721164081
Principal investigator 1 AbbVie Inc. $10,267.75 04/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-431 No dispute reported 06/30/2026 721164371
Principal investigator 1 AbbVie Inc. $3,244.46 04/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721162329
Principal investigator 1 Gilead Sciences, Inc. $1,498.00 04/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088873
Principal investigator 1 Janssen Research & Development, LLC $3,164.00 04/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719485231
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 04/17/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485227
Principal investigator 1 AbbVie Inc. $1,274.48 03/31/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721159439
Principal investigator 1 AbbVie Inc. $927.60 03/30/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-675 No dispute reported 06/30/2026 721158293
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 03/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719485217
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721267055
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721267445
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $68.85 03/26/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Associates
Phase 2 UC No dispute reported 06/30/2026 736758905
Principal investigator 1 AbbVie Inc. $2,594.77 03/25/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
P11-282 No dispute reported 06/30/2026 721156849
Principal investigator 1 Janssen Research & Development, LLC $91.00 03/23/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485205
Principal investigator 1 Gilead Sciences, Inc. $2,015.00 03/18/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 742088867
Principal investigator 1 Gilead Sciences, Inc. $5,968.00 03/18/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088869
Principal investigator 1 Gilead Sciences, Inc. $10,200.00 03/18/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 742088871
Principal investigator 1 Allergan, Inc. $86.00 03/17/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721264651
Principal investigator 1 Janssen Research & Development, LLC $3,499.00 03/16/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists
Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis No dispute reported 06/30/2026 719487587
Principal investigator 1 PFIZER INC. $31,332.00 03/12/2020 Non-covered Recipient Entity
Atlanta Gastro Specialists
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 742953499
Principal investigator 1 AbbVie Inc. $1,287.80 03/02/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-675 No dispute reported 06/30/2026 721154087
Principal investigator 1 Janssen Research & Development, LLC $1,515.00 03/02/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485211
Principal investigator 1 AbbVie Inc. $1,453.20 02/28/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721153569
Principal investigator 1 Janssen Research & Development, LLC $4,464.00 02/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719485223
Recipient Eli Lilly and Company $28.24 02/26/2020 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) No dispute reported 06/30/2026 728717625
Principal investigator 1 Allergan, Inc. $86.00 02/25/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721260287
Principal investigator 1 PFIZER INC. $939.06 02/25/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 742953379
Principal investigator 1 AbbVie Inc. $11,530.86 02/24/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721151907
Principal investigator 1 Gilead Sciences, Inc. $2,229.00 02/24/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease No dispute reported 06/30/2026 742088863
Principal investigator 1 Gilead Sciences, Inc. $14,400.00 02/24/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 742088865
Principal investigator 1 Genentech, Inc. $1,080.90 02/05/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 743032011
Principal investigator 1 AbbVie Inc. $14,378.20 01/31/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-675 No dispute reported 06/30/2026 721148751
Principal investigator 1 AbbVie Inc. $1,196.36 01/31/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721148839
Principal investigator 1 AbbVie Inc. $1,087.20 01/31/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-533 No dispute reported 06/30/2026 721148849
Principal investigator 1 Allergan, Inc. $315.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721250927
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721252533
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721252771
Principal investigator 1 Allergan, Inc. $700.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721253097
Principal investigator 1 Allergan, Inc. $86.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 721254075
Recipient Eli Lilly and Company $70.00 01/28/2020 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 728717553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 01/28/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 737068923
Principal investigator 1 Gilead Sciences, Inc. $1,353.00 01/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 742088859
Principal investigator 1 Gilead Sciences, Inc. $16,144.00 01/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 742088861
Principal investigator 1 Janssen Research & Development, LLC $19,464.00 01/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 719485215
Principal investigator 1 Janssen Research & Development, LLC $1,465.00 01/27/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease No dispute reported 06/30/2026 719485219
Principal investigator 1 Janssen Research & Development, LLC $7,928.00 01/27/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 719487603
Principal investigator 1 Janssen Research & Development, LLC $3,708.00 01/27/2020 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 719487607
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246049
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246069
Principal investigator 1 Allergan, Inc. $700.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246305
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246525
Principal investigator 1 Allergan, Inc. $315.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721246939
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 721247001
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 01/14/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
STUDY OF THE EFFECT OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE IN INDUCTION STUDIES No dispute reported 06/30/2026 737067813
Principal investigator 1 AbbVie Inc. $1,471.04 01/03/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721144511
Principal investigator 1 AbbVie Inc. $1,256.84 01/03/2020 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
M14-234 No dispute reported 06/30/2026 721144513